Shanghai Rightongene Biotechnology Stock Shares Owned By Insiders
| 688217 Stock | 20.75 0.50 2.35% |
Shanghai Rightongene Biotechnology fundamentals help investors to digest information that contributes to Shanghai Rightongene's financial success or failures. It also enables traders to predict the movement of Shanghai Stock. The fundamental analysis module provides a way to measure Shanghai Rightongene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Shanghai Rightongene stock.
Shanghai | Shares Owned By Insiders |
Shanghai Rightongene Biotechnology Company Shares Owned By Insiders Analysis
Shanghai Rightongene's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
More About Shares Owned By Insiders | All Equity Analysis
Insiders Shares | = | Executives Shares | + | Employees |
Current Shanghai Rightongene Shares Owned By Insiders | 40.64 % |
Most of Shanghai Rightongene's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Shanghai Rightongene Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
| Competition |
Based on the latest financial disclosure, 40.64499999999999% of Shanghai Rightongene Biotechnology are shares owned by insiders. This is 167.75% higher than that of the Biotechnology sector and 186.64% higher than that of the Health Care industry. The shares owned by insiders for all China stocks is notably lower than that of the firm.
Shanghai Shares Owned By Insiders Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Shanghai Rightongene's direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Shanghai Rightongene could also be used in its relative valuation, which is a method of valuing Shanghai Rightongene by comparing valuation metrics of similar companies.Shanghai Rightongene is currently under evaluation in shares owned by insiders category among its peers.
Shanghai Fundamentals
| Return On Equity | -0.0148 | ||||
| Return On Asset | -0.0097 | ||||
| Profit Margin | (0.02) % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 987 M | ||||
| Shares Outstanding | 55.86 M | ||||
| Shares Owned By Insiders | 40.64 % | ||||
| Shares Owned By Institutions | 15.60 % | ||||
| Price To Book | 1.28 X | ||||
| Price To Sales | 4.65 X | ||||
| Revenue | 258.21 M | ||||
| Gross Profit | 257.7 M | ||||
| EBITDA | 25.94 M | ||||
| Net Income | 7.93 M | ||||
| Total Debt | 5.82 M | ||||
| Book Value Per Share | 14.70 X | ||||
| Cash Flow From Operations | 45.1 M | ||||
| Earnings Per Share | (0.10) X | ||||
| Number Of Employees | 501 | ||||
| Beta | 0.2 | ||||
| Market Capitalization | 1.16 B | ||||
| Total Asset | 1.04 B | ||||
| Retained Earnings | 154.03 M | ||||
| Working Capital | 467.29 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 1.04 B |
About Shanghai Rightongene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Shanghai Rightongene Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Shanghai Rightongene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Shanghai Rightongene Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Rightongene financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Rightongene security.